GRC17536, another TRPA1 antagonist, showed promise in reducing pain scores in patients with painful diabetic polyneuropathy, highlighting the potential clinical benefits of targeting TRPA1 for pain management [314]. The gene discussed is TRPA1; the disease is diabetic polyneuropathy.